Embecta Corp. reports news on its medical supplies business, centered on insulin delivery products and diabetes-care devices. The company sells pen needles, syringes and safety devices through wholesalers, distributors and institutional channels, and it has described a transition from insulin delivery toward a broader medical supplies platform.
Recurring updates include quarterly operating and financial results, cash dividend declarations, conference participation, board leadership changes, operational updates, capital-structure matters, material agreements, and regulatory or clinical disclosures tied to its device portfolio and manufacturing activities.
Embecta Corp. (NASDAQ: EMBC) announced it will release its financial results for Q2 of fiscal 2022 on May 13, 2022, before market opening. A conference call is set for 8:00 AM ET to discuss the results, provide business updates, and share financial guidance for 2022. Participants can join via phone or a live webcast on the company's investor website. An audio replay will be available post-call. Embecta, focused on diabetes care, leverages a century of insulin delivery experience to support individuals with diabetes.
Embecta Corp. has launched as a leading global diabetes care company, with a history stretching back to 1924. As the largest producer of diabetes injection devices, Embecta manufactures around 8 billion devices annually, serving approximately 30 million patients worldwide. The company estimates the insulin delivery market to be valued at $6 billion to $8 billion per year. With operations spanning over 100 countries and a dedicated workforce of 2,000, Embecta aims to enhance shareholder value through strategic independence and innovation in diabetes care.